197 related articles for article (PubMed ID: 8947918)
1. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models.
Metzger TG; Paterlini MG; Portoghese PS; Ferguson DM
Neurochem Res; 1996 Nov; 21(11):1287-94. PubMed ID: 8947918
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
[TBL] [Abstract][Full Text] [Related]
3. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.
Zaidi SA; Arnatt CK; He H; Selley DE; Mosier PD; Kellogg GE; Zhang Y
Bioorg Med Chem; 2013 Nov; 21(21):6405-13. PubMed ID: 24055076
[TBL] [Abstract][Full Text] [Related]
4. Structure of the δ-opioid receptor bound to naltrindole.
Granier S; Manglik A; Kruse AC; Kobilka TS; Thian FS; Weis WI; Kobilka BK
Nature; 2012 May; 485(7398):400-4. PubMed ID: 22596164
[TBL] [Abstract][Full Text] [Related]
5. 3D modeling, ligand binding and activation studies of the cloned mouse delta, mu; and kappa opioid receptors.
Filizola M; Laakkonen L; Loew GH
Protein Eng; 1999 Nov; 12(11):927-42. PubMed ID: 10585498
[TBL] [Abstract][Full Text] [Related]
6. Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: a comparative study.
Bera I; Laskar A; Ghoshal N
J Mol Model; 2011 May; 17(5):1207-21. PubMed ID: 20661609
[TBL] [Abstract][Full Text] [Related]
7. The design of delta-selective opioid receptor antagonists.
Portoghese PS
Farmaco; 1993 Feb; 48(2):243-51. PubMed ID: 8388215
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
[TBL] [Abstract][Full Text] [Related]
9. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists.
Larson DL; Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
J Med Chem; 2000 Apr; 43(8):1573-6. PubMed ID: 10780914
[TBL] [Abstract][Full Text] [Related]
10. Design of peptidomimetic delta opioid receptor antagonists using the message-address concept.
Portoghese PS; Sultana M; Takemori AE
J Med Chem; 1990 Jun; 33(6):1714-20. PubMed ID: 2160538
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
12. Delta opioid binding selectivity of 3-ether analogs of naltrindole.
Coop A; Pinto J; Wang L; McCullough K; Rothman RB; Dersch C; Jacobson AE; Rice KC
Bioorg Med Chem Lett; 1999 Dec; 9(24):3435-8. PubMed ID: 10617086
[TBL] [Abstract][Full Text] [Related]
13. delta-Opioid receptor: the third extracellular loop determines naltrindole selectivity.
Li X; Varga EV; Stropova D; Zalewska T; Malatynska E; Knapp RJ; Roeske WR; Yamamura HI
Eur J Pharmacol; 1996 Apr; 300(1-2):R1-2. PubMed ID: 8741185
[TBL] [Abstract][Full Text] [Related]
14. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.
Pogozheva ID; Lomize AL; Mosberg HI
Biophys J; 1998 Aug; 75(2):612-34. PubMed ID: 9675164
[TBL] [Abstract][Full Text] [Related]
15. Agonists and antagonists bind to different domains of the cloned kappa opioid receptor.
Kong H; Raynor K; Yano H; Takeda J; Bell GI; Reisine T
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):8042-6. PubMed ID: 8058754
[TBL] [Abstract][Full Text] [Related]
16. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
17. Characterization of [3H]naltrindole binding to delta opioid receptors in mouse brain and mouse vas deferens: evidence for delta opioid receptor heterogeneity.
Fang L; Knapp RJ; Horvath R; Matsunaga TO; Haaseth RC; Hruby VJ; Porreca F; Yamamura HI
J Pharmacol Exp Ther; 1994 Feb; 268(2):836-46. PubMed ID: 8113996
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of a ligand targeting the μ and δ opioid receptors for drug delivery to lung cancer.
Li G; Low PS
Bioorg Med Chem Lett; 2017 May; 27(9):2074-2078. PubMed ID: 28291693
[TBL] [Abstract][Full Text] [Related]
19. Reporter affinity labels: an o-phthalaldehyde derivative of beta-naltrexamine as a fluorogenic ligand for opioid receptors.
Le Bourdonnec B; El Kouhen R; Lunzer MM; Law PY; Loh HH; Portoghese PS
J Med Chem; 2000 Jun; 43(13):2489-92. PubMed ID: 10891107
[No Abstract] [Full Text] [Related]
20. Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells.
Xie Z; Bhushan RG; Daniels DJ; Portoghese PS
Mol Pharmacol; 2005 Oct; 68(4):1079-86. PubMed ID: 16006595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
